An analysis of Neisseria meningitidis strains causing meningococcal septic arthritis in England and Wales: 2010-2020.
Journal
The Journal of infection
ISSN: 1532-2742
Titre abrégé: J Infect
Pays: England
ID NLM: 7908424
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
05
04
2022
revised:
22
07
2022
accepted:
25
07
2022
pubmed:
2
8
2022
medline:
14
9
2022
entrez:
1
8
2022
Statut:
ppublish
Résumé
To analyze clinical meningococcal strains associated with meningococcal septic arthritis cases in England and Wales, and to identify associations between patient age, the synovial joint affected and strain characteristics. IMD cases confirmed by the Meningococcal Reference Unit (UK Health Security Agency) between January 2010 and December 2020 were included in the analysis. Septic arthritis cases were defined as those featuring detection and/or isolation of N. meningitidis from an articular site. Capsular grouping was performed by serology on clinical isolates and/or real-time PCR on clinical samples. We identified 162 cases of meningococcal septic arthritis, representing 2% of all invasive meningococcal disease cases during the study period. The knee and the hip were the most commonly affected joints, with the former significantly more frequent in adults and the latter seen more commonly in children and adolescents. Group B strains were between 2 and 6 times less likely to cause septic arthritis in relation to groups W, C and Y strains. Meningococcal septic arthritis remains a rare manifestation of invasive meningococcal disease. Strain and age associations identified in this study remain unexplained. Future analyzes including clinical case information may help to explain these findings.
Identifiants
pubmed: 35914608
pii: S0163-4453(22)00446-7
doi: 10.1016/j.jinf.2022.07.019
pii:
doi:
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
390-396Informations de copyright
Copyright © 2022. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest GGB, SAC, AW, LW, LLW, JL, XB and RB have performed contract research on behalf of the UK Health Security Agency for Pfizer, GlaxoSmithKline and Sanofi-Pasteur, but received no personal renumeration. No other authors have any conflict of interest to declare.